Ruth Yakar is the founder of BioSight. BioSight has raised $59M in total funding. Latest round: Series C. Based in Airport City, Israel.
Ruth Ben Yakar (also known as Ruth Yakar) is the CEO of BioSight Ltd., an Israel-based clinical-stage biotech company developing therapeutics for hematological malignancies. She leads the company's development of Astrabine (aspacytarabine/BST-236), a drug designed to kill cancer cells while sparing normal cells.
Full founder directory · Investor directory · Company funding database · Fundraising library